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principle for PDT and SDT. Therefore, in vitro comparison of PDT 
and SDT effects can provide insight into SDT mechanism of action. 
We have investigated PDT and SDT effects on human melanoma 
and fibrosarcoma cell lines, previously exposed to 5 aminolevulinic 
acid (Ala), through cell proliferation, cell death, and gene expression 
analysis.
Patients (or Materials) and Methods: The human melanoma, A2058, 
and fibrosarcoma, HT-1080, cell lines were previously exposed to Ala 
(0.45 mM) for 12 and 4 hours, respectively. SW generated by a piezo-
electric device (Piezoson 100, Wolf) were used for SDT. In particular, 
A2058 were treated with an energy flux density (EFD) of 0.32 mJ/
mm2 for 1000 shots (4 shots/sec) while HT-1080 were treated with 
an EFD of 0.43 mJ/mm2 for 500 shots (4 shots/sec). A LED lamp at 
405 nm was used for PDT and both cell lines were treated for 5 min 
at 15 mW. Cell growth was evaluated by WST-1 assay, cell death by 
flow cytometric analysis with SYTOX Green and APC-Annexin V 
and mRNA expression by real-time RT-PCR.
Results: In A2058 both treatments determined a significant cell 
growth reduction even if SDT produced a progressive cell growth 
decrease compared with PDT reaching the greatest decrease at 72 
hours (P < 0.01). Moreover, cell death evaluation highlighted a 25% 
increase of apoptotic cells at 48 hours from SDT. Both PDT and 
SDT determined a significant overexpression of the pro-apoptotic 
gene BAX and of the genes involved in the oxidative stress, NQO1 
and SOD2. In HT-1080, SDT was more effective than PDT with a 
more significant increase of apoptotic cells compared with PDT (P < 
0.01).After both treatments a significant overexpression of the pro-
apoptotic gene APAF1 was observed.
Conclusion: After PDT and SDT a similar gene expression profile 
was observed in both cell lines, even though SDT seems more effective 
on fibrosarcoma cells and PDT on melanoma cells.
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Introduction: Curcumin possesses anticancer, anti-inflammatory, 
antioxidant, and antimicrobial properties. Curcumin has a poor oral 
bioavailability and solubility in plasma. Accordingly, various drug 
delivery systems, such as liposomal preparation, have been developed 
for intravenous administration. However, animal studies have shown 
dose-dependent hemolysis after infusion of liposomal curcumin. 
Because blood cells are the first point of contact for liposomal cur-
cumin when administered intravenously, we investigated the influence 
of curcumin on human red blood cell (RBC) morphology in vitro.
Patients (or Materials) and Methods: Whole blood buffered with 
EDTA was incubated with different concentrations (1, 10, 100 μ g/
mL) of free or liposomal formulations of curcumin. RBC morphology 
and mean cellular volume were examined after 30 minutes, 1 hour, 2 
hours, and 4 hours of incubation.
Results: Dose-dependent echinocyte formation was observed after 
incubation with free and liposomal Curcumin, with a threshold con-
centration of 10 µg/mL and peak effect after 30 minutes of incuba-
tion. Treatment with empty liposomes also resulted in RBC shape 
change. A concomitant increase in mean red blood cell volume was 
detectable.
Conclusion: Curcumin, liposomes and liposomal curcumin dose-
dependently change RBC morphology. This effect is additive and may 
represent a first sign of toxicity following intravenous administration.
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Introduction: In search for drugs that can target cancer cell microen-
vironment in as much as being able to halt malignant cellular trans-
formation, the natural dietary phytochemical curcumin was currently 
assessed in DMH-induced colorectal cancer rat model.
Patients (or Materials) and Methods: The study enrolled 50 animals 
divided into a control group (n = 10) and DMH-induced colorectal 
cancer control group (n = 20) (20 mg/kg.-body weight for 28 weeks) 
versus curcumin-treated group (n = 20) (160 mg/kg suspension daily 
oral for further 8 weeks).
Experimental Procedures: ACF Assay: The colonic lesion biopsies 
were stained by 30% methylene blue for light microscopic examina-
tion [using a 40 magnification to transluminate the specimens] in 
search for lesions fulfilling Mc Lellan and Bird criteria
Histopathological Examination: By using light microscopic 
assessment.
Biochemical Estimations in Colonic Tissues: Malondialdehyde 
(MDA) Assay, reduced glutathione (GSH) Assay, Cyclooygenase-2 
(COX-2) activity measurement, tumor necrosis factor-α (TNF-α 1 
Determination, platelet activating factor (PAF) activity measurement, 
transformaing growth factor-β (TGF-β ) determination:
Results: Treatment by curcumin succeeded to significantly decrease 
the percent of ACF and tended to normalize back the histologic 
changes retrieved in adenomatous and stromal cells induced by 
DMH. The drug also significantly elevated GSH and significantly 
reduced most of the accompanying biochemical elevations (namely 
MDA, TNF-α , TGF-β , and COX2) observed in colonic carcinoma-
tous tissue, induced by DMH, thus succeeding to revert that of MDA, 
COX2& TGF-β back to near normal as justified by being nonsignifi-
cantly altered compared with normal controls. The only exception 
was PAF, which was insignificantly altered by the drug.
Conclusion: When taken together, it could be concluded that cur-
cumin possess the potentiality to halt some of the orchestrated cross-
talk between cancerous transformation and its microenvironmental 
niche that contributes to cancer initiation, progression, and metasta-
sis in this experimental cancer colon model. Envisioning these merits 
to a drug with an already known safety preferentiality, awaits final 
results of current ongoing clinical trials, before curcumin can be 
added to the new therapeutic armamentarium of anticancer therapy.
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Introduction: Cytochrome P 450 enzymes (CYPs) were presumed 
to play a role in the oxidation of intermediate metabolites of busul-
fan (Bu). In vitro elucidation of involvement of CYPs in the oxi-
dation of Bu metabolites is cumbersome due to the volatile nature 
of tetrahydrothiophene and nonavailability of sensitive quantita-
tion methods. This study is aimed at exploring the association of 
CYP2C9, CYP2C19, CYP2B6, FMO genotypes, and sulfolane (Su) 
levels in children undergoing hematopoietic stem cell transplantation 
(HSCT).The relation of genotypes with the outcomes of HSCT was 
also explored.
Patients (or Materials) and Methods: Sixty-six children receiving IV 
Bu-based myeloablative conditioning regimen were genotyped for 
common functional variant alleles in CYP2C9 (*2 and *3), CYP2C19 
(*2 and *17), FMO3 (rs2266780, rs2266782 and rs1736557) and 
CYP2B6 (*5 and *9). Plasma levels of Bu and its metabolite Su were 
measured after dose 9 from a subset of 44 patients for whom plasma 
samples after dose 9 were available. The ratio of Bu to Su was taken 
as a metabolic ratio (MR) to compare among genotype groups. The 
MRs (Bu/Su), Bu and Su levels between different genotype groups 
were compared using nonparametric tests. The distribution of age, 
and gender between the groups was compared using t test and chi-
square test, respectively. Cumulative incidence of overall survival and 
event-free survival were estimated using Kaplan-Meier curves and 
log-rank test was used to compare the difference between genotype 
groups or groups divided on the basis of MR, in a univariate analysis. 
Multivariate analysis was performed using cox-regression analysis.
Results: Higher metabolic ratios (MRs, Bu/Su) were observed in 
CYP2C9*2 and *3 allele carriers (mean [SD], 7.8 [3.6] Vs 4.4 [2.2]; 
P = 0.003). Lower event-free survival was seen in patients with MR 
above the median 5 (40% vs 79%; P = 0.009) and carrying reduced 
function alleles of CYP2B6 (40% vs 84%; P = 0.005).
Conclusion: This study suggests the role of the CYP2C9 in the oxi-
dation reactions of THT and CYP genotypes along with Bu MRs 
to be important at predicting outcomes of Bu based myeloablative 
conditioning before HSCT.
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Introduction: Nevirapine (NVP) is a non-nucleoside reverse tran-
scriptase inhibitor (NNRTI) widely used in antiretroviral therapy 
(ART) in sub-Saharan Africa. Approximately 5% of patients 
receiving NVP-containing regimens develop hypersensitivity reac-
tions (HSRs). These can manifest as more severe reactions includ-
ing Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis 
(TEN), and hepatotoxicity. Various human leukocyte antigen (HLA) 
alleles have been associated to NVP-induced HSRs in populations 
of differing ethnicity. Carriage of HLA-C*04:01 is associated with 
an increased risk of SJS in our Malawian cohort. We investigated 
whether expression levels of miR-148a, a microRNA known to regu-
late HLA-C expression, differ in serum samples from hypersensitive 
and tolerant patients. The aim of the study was to identify the role 
of posttranscriptional regulation of HLA-C expression in HLA-
associated NVP-induced HSRs.
Patients (or Materials) and Methods: A total of 1117 HIV-positive 
patients in Malawi treated with a NVP-containing regimen were 
recruited prospectively. Of these, 57 patients developed NVP-induced 
HSRs. MicroRNA expression was analyzed using TaqMan probe–
based qPCR in available serum samples of 41 tolerant and 33 hyper-
sensitive patients. Expression levels were compared in hypersensitive 
patients at baseline (n = 19) and during the acute phase of the reac-
tion (n = 26). Tolerant baseline (n = 25) and week 6 (n = 27) samples 
were used as controls. Data were analyzed using nonparametric tests.
Results: There was no significant difference in the baseline expres-
sion of miR-148a between tolerant and hypersensitive patients. In 
our cohort, miR-148a expression showed a 4.6-fold increase in acute 
hypersensitive samples, when compared with baseline hypersensitive 
(P = 0.008). This was not observed in samples from tolerant patients.
Conclusion: Our study has identified an increase in miR-148a 
expression levels in serum samples from Malawian nevirapine 
hypersensitive patients during the acute phase. The reason(s) for the 
change in expression during the acute phase are unclear but may be 
related to the ongoing inflammation associated with a HSR. Further 
investigation is required to elucidate the mechanism of the rise in 
microRNA levels and any implications this may have on the severity 
and duration of the HSR.
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Introduction: Resistance to anticonvulsants affects one third of all 
epilepsy patients. Limited bioavailability of the drug at the target site 
caused by increased expression of efflux transporters on the blood 
brain barrier or alterations of target genes as well as seizure-induced 
neural reorganization are potential mechanisms for therapy resist-
ance. There is increasing evidence that expression of microRNAs 
(miRNAs) is deregulated in neuronal disorders. We hypothesize that 
an altered miRNA regulation of target genes is involved in drug 
resistance in epilepsy.
Patients (or Materials) and Methods: Hippocampal focal and corti-
cal nonfocal brain tissue samples from 13 patients diagnosed with 
MTS (mesial temporal sclerosis) who underwent neurosurgery have 
been screened for miRNA expression using TaqMan® low-density 
arrays. To compare miRNA expression between brain regions, a 
Mann-Whitney U test was performed using R (Bioconductor). In 
silico approaches for both a hypothesis-based (efflux-transporter 
and target gene) as well as a hypothesis-free approach were used 
